South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Circle Pharma is raising $45,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Earp played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Circle Pharma

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development.

To learn more about Circle Pharma, visit http://www.circlepharma.com/

Contact:
David Earp, Chief Executive Officer
650-392-0350
https://www.linkedin.com/in/david-j-earp-jd-phd-584ba03/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved